Cargando…
Clinical Trial of Four Weeks of Combination Therapy with Low-dose Methimazole and a Cholesterol Absorption Inhibitor as the Initial Treatment for Childhood-onset Graves’ Disease
The initial treatment of childhood-onset Graves’ disease is based on the result of clinical trials of adult-onset disease. The major adverse events associated with methimazole, the only medication approved for childhood-onset disease in Japan, are considered to depend on the dose, and the risk of ad...
Autores principales: | Takakuwa, Satoshi, Kina, Yoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society for Pediatric Endocrinology
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924173/ https://www.ncbi.nlm.nih.gov/pubmed/24532957 http://dx.doi.org/10.1297/cpe.23.17 |
Ejemplares similares
-
Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves’ disease
por: Lee, Hyun Gyung, et al.
Publicado: (2021) -
Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023) -
Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up
Study
por: Matsushita, Rie, et al.
Publicado: (2010) -
Methimazole-Induced Pleural Effusion in the Setting of Graves' Disease
por: Khine, Le Yu, et al.
Publicado: (2019) -
Transdermal Absorption of Methimazole- a Cat’s Tale
por: Mittal, Ashima, et al.
Publicado: (2021)